Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 and closed at $28.50 on its first trading day on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its Nasdaq debut on November 13, 2026, with shares closing sharply higher than their offering price on the first day of trading.
The Shanghai-rooted company priced its initial public offering at $17.00 per share under the ticker symbol WWB. By the closing bell, shares had reached $28.50, representing a gain of roughly 68 percent from the IPO price — a strong first-day performance by any measure in the current biotech capital markets environment.
Read more SEC Trading and Markets Director Addresses Data Challenges →
Windward Bio operates in the immunology space, a therapeutic area that has drawn sustained investor interest as drugmakers pursue next-generation treatments for autoimmune and inflammatory conditions. The company's listing adds to a growing pipeline of China-linked biotechs seeking U.S. public market access through Nasdaq.
Qiming Venture Partners, the venture capital firm behind the company, has built a track record of backing life sciences startups across Asia. Windward Bio's successful listing signals continued appetite among institutional investors for early-stage immunology platforms, even amid broader uncertainties in the biotech sector.
Continue reading at All Financial Services & Investing.
